Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Viridian Therapeutics (VRDN) Stock Price & Analysis

1,572 Followers

VRDN Stock Chart & Stats

$30.48-$0.77(-2.46%)
At close: 4:00 PM EST
$20$25$30Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$30.31 - $31.30
52-Week Range
$13.18 - $34.29
Previous Close
$31.25
Volume
N/A
Average Volume (3M)
2.69M
Market Cap
$3.50B
Enterprise Value
$1.72B
Total Cash (Recent Filing)
$955.21M
Total Debt (Recent Filing)
$243.27M
Price to Earnings (P/E)
―
Beta
0.42
Next Earnings
Mar 11, 2027 (Est.)
EPS Estimate
-0.72
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Early Lumvoa Commercial Adoption

The initial Lumvoa launch provides evidence that Viridian has moved beyond development toward commercial revenue generation. Patient starts and demand-driven sales create a foundation for broader adoption, future revenue growth, and operating leverage as launch infrastructure matures.

Pipeline And Regulatory Execution

Progress toward the elegrobart BLA and additional clinical programs diversifies Viridian's growth prospects beyond Lumvoa. The pipeline could support follow-on products, expand autoimmune indications, and reuse the commercial infrastructure already built for the company's lead therapy.

Substantial Funding Position

A large cash and marketable-securities balance gives Viridian resources to fund clinical development, regulatory submissions, and commercialization without immediate dependence on additional financing. This strengthens execution flexibility while the company advances toward profitability.

Bears Say

Heavy Cash Burn

Persistent and worsening cash outflows show that Viridian's current operations are not self-funding. Continued investment in commercialization and development will consume substantial resources, making progress toward profitability and disciplined capital allocation important over the next several quarters.

Deepening Unprofitability

Large losses and deeply negative margins indicate that Viridian has not yet established sustainable earnings from its commercial transition. Until revenue scales materially, profitability remains dependent on successful product adoption, cost control, and eventual operating leverage.

Payer Coverage Still Developing

Incomplete payer coverage can slow patient access and delay the conversion of clinical demand into recurring product revenue. Viridian must continue securing policies across differing payer timelines, so near-term commercial growth remains exposed to reimbursement execution.

Viridian Therapeutics News

VRDN FAQ

What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $13.18 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $3.50B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 118 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Nov 04, 2026. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$1.015 by $0.205.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -0.72.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 113,558,450 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$0.81 in its last earnings report, beating expectations of -$1.015. Following the earnings report the stock price went up 15.527%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Hedge funds hold Viridian Therapeutics shares: the largest hedge-fund position in Viridian Therapeutics is 71,887,055 shares, and hedge funds increased their holdings by 1.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology